dalteparin has been researched along with Glioma in 4 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adults with newly diagnosed malignant glioma were randomized to receive dalteparin 5000 anti-Xa units or placebo, both subcutaneously once daily for 6 months starting within 4 weeks of surgery." | 9.14 | PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. ( Agnelli, G; Baker, R; Falanga, A; Finch, T; Geerts, W; Julian, JA; Laperriere, NJ; Levine, MN; Malkin, MG; Parpia, S; Perry, JR; Rogers, LR; Sawaya, R, 2010) |
| "Adults with newly diagnosed malignant glioma were randomized to receive dalteparin 5000 anti-Xa units or placebo, both subcutaneously once daily for 6 months starting within 4 weeks of surgery." | 5.14 | PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. ( Agnelli, G; Baker, R; Falanga, A; Finch, T; Geerts, W; Julian, JA; Laperriere, NJ; Levine, MN; Malkin, MG; Parpia, S; Perry, JR; Rogers, LR; Sawaya, R, 2010) |
| "Spontaneous intracranial hemorrhage (ICH) is also a frequent occurrence in these patients, but there is limited data on the safety of therapeutic anticoagulation." | 1.46 | Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. ( Mantia, C; Neuberg, D; Puligandla, M; Uhlmann, EJ; Weber, GM; Zwicker, JI, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mantia, C | 1 |
| Uhlmann, EJ | 1 |
| Puligandla, M | 1 |
| Weber, GM | 1 |
| Neuberg, D | 1 |
| Zwicker, JI | 1 |
| Balzarotti, M | 1 |
| Fontana, F | 1 |
| Marras, C | 1 |
| Boiardi, A | 1 |
| Croci, D | 1 |
| Ciusani, E | 1 |
| Salmaggi, A | 1 |
| Perry, JR | 1 |
| Julian, JA | 1 |
| Laperriere, NJ | 1 |
| Geerts, W | 1 |
| Agnelli, G | 1 |
| Rogers, LR | 1 |
| Malkin, MG | 1 |
| Sawaya, R | 1 |
| Baker, R | 1 |
| Falanga, A | 1 |
| Parpia, S | 1 |
| Finch, T | 1 |
| Levine, MN | 1 |
| Perry, SL | 1 |
| Bohlin, C | 1 |
| Reardon, DA | 1 |
| Desjardins, A | 1 |
| Friedman, AH | 1 |
| Friedman, HS | 1 |
| Vredenburgh, JJ | 1 |
2 trials available for dalteparin and Glioma
| Article | Year |
|---|---|
PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Neoplasms; Dalteparin; Factor Xa; Female; Glio | 2010 |
Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.
Topics: Adult; Aged; Brain Neoplasms; Drug Administration Schedule; Female; Fibrinolytic Agents; Follow-Up S | 2009 |
2 other studies available for dalteparin and Glioma
| Article | Year |
|---|---|
Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Neoplasms; Cohort Studies; Enoxaparin; Female; | 2017 |
In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas.
Topics: Adolescent; Adult; Aged; Apoptosis; Brain Neoplasms; Cell Proliferation; Dose-Response Relationship, | 2006 |